VP和MVP方案治疗晚期非小细胞肺癌疗效的随机对照研究

通过比较VP和MVP两组方案治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的疗效和毒性,探讨MVP方案中MMC的应用价值。58例晚期NSCLC患者入组,其中VP方案组(VDS+DDP)28例,MVP方案组(MMC+VDS+DDP)30例,每例患者至少化疗3个周期。疗效及不良反应评价均按WHO标准进行。结果显示,VP组和MVP组有效率分别为46·4%(13/28)和50·0%(15/30),差异无统计学意义,P>0·05;1年生存率、中位生存期在MVP和VP组分别为30·0%(9/30)和39·3%(11/28),9·6和11·5个月。主要毒副反应均为骨髓抑制和胃肠道反应,但MVP组明显较重。初步研究结果提示,MMC的加入对MVP方案无益,毒性相对增加,应予舍弃。

Comparative study of therapeutic effects of VP and MVP regimens in advanced non-small cell lung cancer

The objective of this study was to compare the efficacy and toxicity of VP and MVP regimens for advanced non-small cell lung cancer (NSCLC). A total of 58 cases of advanced non-small cell lung cancer were enrolled. Among them, 28 cases were treated with VP regimen and 30 cases with MVP regimen. Each patient received at least 3 cycles of chemotherapy. The responses and the side effects were evaluated according to the WHO criteria. The response rates were 50.0% (15/30) for MVP regimen and 46.4%(13/28) for VP regimen, respectively. There was no statistically significant difference (P>0.05) between them. The 1-year survival vate was 30.0%(9/30) in MVP group and 39.3%(11/28) in VP group.The median survival duration was 9.6 months in MVP group and 11.5 months in VP group. The major toxicities were myelosuppression and digestive tract reaction and those of MVP group were obviously heavier. The results of this study demonstrated that VP regimen had a rather efficacy than MVP for advanced non-small cell lung cancer (NSCLC). In conclusion, the MMC makes opposite increment of toxicity and should be abandoned.